Mono-Immunotherapy in Non-Small Cell Lung Cancer: Controversies and Challenges

the

[1]  F. Skoulidis,et al.  Trial in progress: A phase 2 study of sotorasib as first-line treatment in patients with stage IV non–small cell lung cancer (NSCLC) whose tumors harbor a KRAS p.G12C mutation (CodeBreaK 201). , 2022, Journal of Clinical Oncology.

[2]  G. Aktas,et al.  Letter to the Editor Concerning Diminished Efficacy of Programmed Death-(Ligand) 1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status. , 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  Jared C Malke,et al.  Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response , 2021, Science.

[4]  Y. Lou,et al.  Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR , 2021, Frontiers in Oncology.

[5]  Lihong V Wang,et al.  Response to PD-1-Based Immunotherapy for Non-Small Cell Lung Cancer Altered by Gut Microbiota , 2021, Oncology and Therapy.

[6]  M. Bersanelli,et al.  The gut microbiome and efficacy of cancer immunotherapy. , 2021, Pharmacology & therapeutics.

[7]  A. Cortellini,et al.  Antibiotic-exposed patients with non-small cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  K. To,et al.  Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies , 2021, Frontiers in Oncology.

[9]  C. Dooms,et al.  Patient-reported outcomes (PRO) from the phase 2 CodeBreaK 100 trial evaluating sotorasib in KRAS p.G12C mutated non-small cell lung cancer (NSCLC). , 2021 .

[10]  G. Yancopoulos,et al.  Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial , 2021, The Lancet.

[11]  T. Gajewski,et al.  Microbiome-based interventions: therapeutic strategies in cancer immunotherapy , 2020, Immuno-oncology technology.

[12]  David T. W. Tzeng,et al.  The Gut Microbiome Is Associated with Clinical Response to Anti–PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer , 2020, Cancer Immunology Research.

[13]  M. Ladanyi,et al.  Precision Medicine in Non-Small Cell Lung Cancer: Current Applications and Future Directions. , 2020, Seminars in cancer biology.

[14]  J. Lunceford,et al.  LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in Keynote-042 , 2019 .

[15]  Myung Ah Lee,et al.  The effect of antibiotics on the clinical outcomes of patients with solid cancers undergoing immune checkpoint inhibitor treatment: a retrospective study , 2019, BMC Cancer.

[16]  S. Digumarthy,et al.  Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  D. de Ruysscher,et al.  Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[18]  N. Schultz,et al.  EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  Jianying Zhou,et al.  Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial , 2019, The Lancet.

[20]  Matthew D. Hellmann,et al.  First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J. Szustakowski,et al.  Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden , 2018, The New England journal of medicine.

[22]  L. Zitvogel,et al.  Cancer immunotherapy in 2017: The breakthrough of the microbiota , 2018, Nature Reviews Immunology.

[23]  Laurence Zitvogel,et al.  Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors , 2018, Science.

[24]  E. Le Chatelier,et al.  Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients , 2018, Science.

[25]  Yi-long Wu,et al.  EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer , 2017, Oncoimmunology.

[26]  Ian D. Wilson,et al.  Gut microbiota modulation of chemotherapy efficacy and toxicity , 2017, Nature Reviews Gastroenterology &Hepatology.

[27]  V. Gebski,et al.  Checkpoint Inhibitors in Metastatic EGFR‐Mutated Non–Small Cell Lung Cancer—A Meta‐Analysis , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[28]  Y. Huang,et al.  Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[29]  S. Digumarthy,et al.  Diminished Ef fi cacy of Programmed Death-(Ligand)1 Inhibition in STK11 - and KEAP1 -Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status , 2022 .